Condition
Advanced Solid Tumor Malignancy
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results67% success
Data Visualizations
Phase Distribution
3Total
P 1 (3)
Trial Status
Completed2
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT04260529Phase 1CompletedPrimary
CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations
NCT05501821Phase 1CompletedPrimary
Study of KBA1412 in Participants With Advanced Solid Malignant Tumors
NCT02380677Phase 1TerminatedPrimary
Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors
Showing all 3 trials